Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

What happened: Roche presented interim phase III IMAgINATION data showing investigational sefaxersen reduced proteinuria in adults with primary IgA nephropathy on optimised standard of care. Key numbers: 43.1% reduction in proteinuria versus placebo at 37 weeks (95% CI: 32.5 to 52.0, P<0.0001); 459 people enrolled, randomised 1:1 for 105 weeks; once-monthly Why it matters: Roche said the results support sefaxersen as a potential novel approach to slow IgAN progression, and the blinded study continues to week 105 to assess eGFR change, with data to be shared with health authorities.

Roche presented interim phase III IMAgINATION data showing investigational sefaxersen reduced proteinuria in adults with primary IgA nephropathy on optimised standard of care.

Roche said the results support sefaxersen as a potential novel approach to slow IgAN progression, and the blinded study continues to week 105 to assess eGFR change, with data to be shared with health authorities.